BESPOKE: ctDNA Clearance During and After ACT

Opinion
Video

Panelists discuss how circulating tumor DNA (ctDNA) clearance rates during and after adjuvant chemotherapy (ACT) in the BESPOKE trial provide critical insights into treatment efficacy and may serve as an early predictor of long-term patient outcomes.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
Related Content